The global peptide CDMO market, in its telling, has gone from a $1-1.5 billion category to $5-6 billion in just a few years and most of that explosion is downstream of GLP-1s success, which has made innovators want to develop the next generation of peptide drugs
The Science Behind Collagen: Boosting Skin's Strength and Elasticity Collagen is crucial for maintaining the skin's strength, suppleness, and beauty
Extended Data Figure 4 Effects of binding pocket mutations on potency of NAMs
This multi-agent approach, increasingly supported by dermatology literature, is only possible through compounding
China: Not yet approved as a novel food ingredient by the National Health Commission (NHC)
Noom Med with Smart Rx , in partnership with Waltz Health, drives significant ROI for employers who wish to cover GLP-1s as a supplemental benefit such that the payer can choose the level of financial assistance they will provide Noom Weight with GLP-1 Rx delivers a proven obesity program and employee-pay access to affordable GLP-1s for employers who choose not to cover GLP-1s today New York, NY October 21, 2024 Noom, the leading digital healthcare company committed to chronic disease prevention and empowering people to live better longer, is tackling the problem of GLP-1 availability, accessibility and inflated costs head-on by launching two distinct enterprise solutions that reduce obesity management costs while enabling access to life-changing medications: Noom Med with Smart Rx in partnership with Waltz Health and Noom Weight with GLP-1 Rx